Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

Jia Luo, Tomasz (Tom) Beer, Julie N. Graff

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Patients with nonmetastatic castration-resistant prostate cancer (CRPC) are a heterogeneous population with regard to risk of progression to metastatic disease. Treatment selection for nonmetastatic CRPC must balance the risk of disease progression with the side effects of available therapies. Several medication classes are available for use in treating these patients, and other newer agents are under active clinical trial investigation. Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.

Original languageEnglish (US)
Pages (from-to)336-344
Number of pages9
JournalOncology (Williston Park, N.Y.)
Issue number4
StatePublished - Apr 1 2016

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment of Nonmetastatic Castration-Resistant Prostate Cancer'. Together they form a unique fingerprint.

Cite this